Announcement of Syngene International

Syngene International developed ELISA Antibody testing kit for COVID-19 will be manufactured and distributed by HiMedia Laboratories

While RT-PCR kits are the gold standard in COVID-19 diagnostics, rapid antibody tests are a globally acknowledged method for quick surveillance and community risk management. Most of these antibody kitswere hitherto being imported. But supply chains worldwide are seriously hampered and diverted and grave misgivings have recently surfaced about quality and efficacy of these imported kits.

The Kits will be sent to National Institute of Virology, Pune, for validation and when approved will be a major enabling step towards Aatmanirbharbharat in terms of enhancing testing capabilities. It also comes at an extremely opportune time when ICMR has widened testing protocol to survey for community exposure especially among vulnerable groups through rapid ELISA tests.

C-CAMP CEO and Director, Dr. Taslimarif Saiyed, also Convener of the NBRIC Governing Council, said “As number of cases scales new peaks every day, rapid antibody tests, quick triaging and contact tracing will be of critical importance in containing the virus. Given the emphasis on indigenous manufacturing and selfreliance, the Syngene-HiMedia collaboration is an exciting development with potential far-reaching impact on our testing capacity. ”

Constituted by Department of Biotechnology, Government of India and hosted, convened by C-CAMP,NBRIC is a collaborative Public Private Partnership to drive indigenous innovation focused on developing reagents, diagnostics, vaccines and therapeutics for COVID19 and beyond.

About Syngene: